Kiniksa (KNSA) news
Recent news
Kyniska Pharmaceuticals Q2 EPS USD 0.3
Kiniksa Pharmaceuticals reported second quarter 2026 financial results, with net income of $17.8 million, translating to EPS of $0.30 on basic and $0.23 on a diluted basis. This represents a significant improvement from the second quarter of 2024, when the company recorded a net loss of $3.9…
AInvest Wire · Jul 28, 2026Jefferies raises target price to $78 from $71 for Kiniksa Pharmaceuticals International, PLC
Jefferies has raised its target price for Kiniksa Pharmaceuticals International, PLC (Nasdaq: KNSA) to $78 from $71, reflecting a positive reassessment of the company’s financial outlook and performance. The adjustment follows recent developments, including Kiniksa’s participation in the 2024…
AInvest Wire · Jul 13, 2026Dubai's Salik to pay AED471m to the federal tax authority
Dubai-based toll operator Salik has announced a payment of AED471 million to the Federal Tax Authority, as part of its ongoing compliance with Value Added Tax (VAT) and excise tax obligations. The payment reflects the company’s commitment to adhering to the UAE’s tax regulations, which require…
AInvest Wire · May 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.